Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive first-line chemo-immunotherapy for peripheral T-cell lymphoma
2006-004234-33Phase 2Terminated
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of alemtuzumab in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoints: Complete clinical response at one year and Efficacy of innovative therapies in non-Hodgkin peripheral T-cell lymphomas. Started Feb 2007; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2006-004234-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004234-33.